Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere.

Published

Journal Article

For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

Full Text

Duke Authors

Cited Authors

  • Woodward, DF; Wang, JW; Stamer, WD; Lütjen-Drecoll, E; Krauss, AH-P; Toris, CB

Published Date

  • November 2019

Published In

Volume / Issue

  • 35 / 9

Start / End Page

  • 469 - 474

PubMed ID

  • 31329508

Pubmed Central ID

  • 31329508

Electronic International Standard Serial Number (EISSN)

  • 1557-7732

Digital Object Identifier (DOI)

  • 10.1089/jop.2019.0041

Language

  • eng

Conference Location

  • United States